<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Anca on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/anca/</link><description>Recent content in Anca on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Wed, 29 Jul 2026 15:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/anca/index.xml" rel="self" type="application/rss+xml"/><item><title>Drug- and Vaccine-Induced ANCA-Associated Vasculitis</title><link>https://rheumatologydigest.org/posts/drug-vaccine-induced-anca-vasculitis/</link><pubDate>Wed, 29 Jul 2026 15:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/drug-vaccine-induced-anca-vasculitis/</guid><description>A 2026 overview of drug- and vaccine-induced ANCA-associated vasculitis — clinically near-indistinguishable from idiopathic AAV, but with a recognisable serological fingerprint (dual MPO/PR3 positivity, elastase-ANCA, high IgM MPO-ANCA, low C4, neutropenia), a milder course, and one intervention no immunosuppressant can substitute for: stopping the drug. Antithyroid drugs, hydralazine and levamisole-adulterated cocaine dominate practice.</description></item></channel></rss>